Premium
Gastric cancer: Basic aspects
Author(s) -
Duarte Henrique O.,
Gomes Joana,
Machado José C.,
Reis Celso A.
Publication year - 2018
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12523
Subject(s) - cancer , medicine , malignancy , clinical trial , disease , personalized medicine , precision medicine , bioinformatics , intensive care medicine , biology , pathology
Despite major breakthroughs in the field of personalized medicine, gastric cancer ( GC ) remains a clinically challenging disease, characterized by scarce effective treatment options and the lack of reliable molecular tools for the prediction of patient outcome and response to therapy. The pronounced molecular heterogeneity that dictates the phenotypical aggressiveness of gastric neoplasms severely limits the antitumor efficacy of targeted agents brought to clinical trials, and constitutes a favorable setting for the emergence of refractory tumors exhibiting multidrug resistance. We will review the most recent advances in our understanding of GC biology, which are underlying the development and clinical testing of novel targeted therapeutic agents. We will also emphasize how their efficacy and acquired resistance relate to the aberrant molecular signatures that drive gastric malignancy.